Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab plus paclitaxel, cisplatin, and radiotherapy for locally recurrent or oligometastatic endometrial carcinoma
ChiCTR2400087571Phase 2Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Jul 2024
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab, paclitaxel and cisplatin in endometrial cancer (EC), sponsored by Shandong Cancer Hospital. Primary endpoint: Progression-free survival. Started Jul 2024; status: recruiting.
02
Drugs
cadonilimabpaclitaxelcisplatin
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on ChiCTR2400087571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087571.